OSLO,
Norway, July 4, 2022 /PRNewswire/ -- Navamedic
ASA (OSE: NAVA) today announces a trading update based on updated
estimated revenue growth in excess of 30% organic growth for the
first half of 2022. The high revenue growth is a result of a strong
June 2022 and is driven by
significant demand for Mysimba as well as other key products in the
portfolio.
As the company's preliminary consolidated financial results for
the second quarter of 2022 (and hence first half of the year)
represent a noticeable improvement compared to expectations, the
company has decided to provide a trading update based on estimated
organic revenue growth for the first half of 2022 in excess of 30%.
As this estimate includes only organic growth, it does not take
into account any revenues from the announced acquisition of Impolin
AB, which was completed on 1 June
2022. There is reason to believe that a portion of the
growth to a certain degree is related to stock-up at the
wholesalers.
"The accelerated revenue growth in June implies that the second
quarter was record strong for Navamedic, with more than
NOK 100 million in quarterly revenues
for the first time. During the first few months of 2022 one of our
most important products, the obesity drug product, was out of stock
due to supply chain issues outside of Navamedic's control. We are
happy that we once again were able to supply Mysimba to wholesalers
as of early June, which contributed to the strong quarter," says
Kathrine Gamborg Andreassen, Chief
Executive Officer of Navamedic ASA.
Navamedic emphasizes that the financial statements for Q2 2022
are yet to be closed, that the revenue growth indicated thus at
this stage is an estimate, and that the final numbers will be
communicated in connection with Navamedic's presentation of the Q2
results on August 12, 2022.
This information is considered to be inside information pursuant
to the EU Market Abuse Regulation and is subject to the disclosure
requirements pursuant to Section 5-12 the Norwegian Securities
Trading Act. The information was submitted for publication, through
Newsweb by Lars Hjarrand at 19.24 hrs CET on 4 July 2022.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO,
Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
About
Navamedic ASA is a Nordic pharma company and reliable provider
of high-quality products, delivered to hospitals and through
pharmacies, meeting the specific needs of patients and consumers by
leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in
all the Nordic countries, the Baltics and Benelux, with sales
representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa--trading-update,c3596457